Drugs / Dexmedetomidine
Dexmedetomidine
English name dexmedetomidine
also known as
DEX · Precedex · Dexmedetomidine Hydrochloride · Dexdor · DXM · BXCL501 · Dexmedetomidin · Dexmedetomidine injection · +37 more
Other / unclassified targets ADRA2A via activation
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | IGALMI | — | 2025-11-19 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | PRECEDEX | — | 2008-10-17 – 2022-12-16 | fda.gov ↗ |
| Label expansion | US (FDA) | DEXMEDETOMIDINE HYDROCHLORIDE | — | 2016-09-19 | fda.gov ↗ |
| Approved | EU (EMA) | Dexdor | — | 2011-09-15 | europa.eu ↗ |
| Approved | US (FDA) | PRECEDEX | — | 1999-12-17 | fda.gov ↗ |
Trials 1,078 · started per year
today
US approved 1999
EU approved 2011
1
3
6
12
9
9
14
13
24
39
27
67
49
62
70
52
59
58
78
62
72
103
97
91
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 033 trials · 1 met primary · 1 missed | ||||||
| Phase 0 | NCT06824077 | Oct 2026 → Mar 2027 expected | delirium | University of Alberta | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07800910 | Sep 2026 → Aug 2028 expected | circadian rhythm sleep disorder | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07866508 | Aug → Oct 2026 expected | — | Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad | Active not recruiting | No outcome recorded |
| Phase 0 | NCT07211399 | Jul 2026 → Dec 2030 | substance-related disorder | Jacques E. Chelly | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT07502651 | May 2025 → Mar 2027 expected | — | Postgraduate Institute of Dental Sciences Rohtak | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06756178 | Jan 2025 → Nov 2026 expected | delirium | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05264077 | Nov 2024 → Jun 2025 overdue | — | Sheikh Zayed Medical College | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06229054 | Feb → Jul 2024 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT06215768 | Jan → Sep 2024 | delirium | Esraa Abdel Azez Soltan Mohamed Zayed | Unknown | No outcome recorded |
| Phase 0 | NCT07651488 | Mar → Sep 2023 | — | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 0 | NCT05505630 | Jan 2023 → Dec 2025 | nicotine dependence | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT05574179 | Jan → Jul 2023 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 0 | NCT05351489 | May 2022 → Oct 2023 | — | Mansoura University | Completed | No outcome recorded |
| Phase 0 | NCT05435560 | Apr 2022 → Apr 2023 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03757897 | Dec 2021 → Dec 2022 | intracranial hypertension | Yale University | Withdrawn | No outcome recorded |
| Phase 0 | NCT05244252 | Oct 2021 → Mar 2022 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 0 | NCT05246371 | Jun → Nov 2021 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT03817034 | Mar 2021 | — | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 0 | NCT04757675 | Mar → Sep 2021 | separation anxiety disorder | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| Phase 0 | NCT04646317 | Dec 2020 → Mar 2021 | gallbladder disorder, hypertensive disorder | Dr. Ruth K.M. Pfau Civil Hospital, Karachi | Unknown | No outcome recorded |
| Phase 0 | NCT04436731 | Dec 2020 → Jun 2026 overdue | obesity disorder | University of Missouri-Columbia | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT04142840 | Nov 2019 → Aug 2021 | — | RenJi Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04171349 | Jun → Oct 2019 | kidney failure | Ain Shams University | Completed | Met primary |
| Phase 0 | NCT03770130 | Jan 2019 → Oct 2022 | — | RenJi Hospital | Completed | Missed primary |
| Phase 0 | NCT03738059 | Nov 2018 → Mar 2019 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT03719001 | Oct 2018 → Jun 2022 | vascular disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 0 | NCT03596775 | Sep 2018 → Jun 2019 | — | Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT03095469 | Aug → Nov 2017 | — | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 0 | NCT03466242 | Jan 2017 → Jan 2020 | — | Phoenix Children's Hospital | Withdrawn | No outcome recorded |
| Phase 0 | NCT02529202 | Mar → Nov 2016 | brain hypoxia - ischemia | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02768688 | Jul 2014 → Feb 2017 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 0 | NCT01927640 | Feb 2013 → Jan 2014 | acute coronary syndrome, intermediate coronary syndrome | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 142 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT07818330 | Oct → Dec 2026 expected | — | Teikoku Pharma USA, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05619627 | Aug 2026 → Aug 2027 expected | — | Children's Mercy Hospital Kansas City | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07167316 | May → Dec 2026 expected | — | Hans-Peter Landolt | Recruiting | No outcome recorded |
| Phase 1 | NCT07603596 | May 2026 → Apr 2028 expected | delirium, digestive system neoplasm | Qianfoshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07677917 | Jan → Jul 2026 overdue | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06335407 | Jul 2025 → Feb 2027 expected | alcohol-related disorders, post-traumatic stress disorder | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | Recruiting | No outcome recorded |
| Phase 1 | NCT07023991 | May → Aug 2025 overdue | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07140627 | Aug 2024 → Jan 2025 | — | Allama Iqbal Medical College | Completed | No outcome recorded |
| Phase 1 | NCT06304909 | May 2024 → Mar 2025 | — | Assiut University | Completed | Met primary |
| Phase 1 | NCT06631625 | Sep 2023 → Sep 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 1 | NCT07051512 | Jul 2023 → Jun 2024 | — | Tanta University | Completed | No outcome recorded |
| Phase 1 | NCT06614010 | Feb 2023 → Sep 2025 overdue | — | Qianfoshan Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05880693 | Jan 2022 → Apr 2023 | hypotensive disorder | mohamed | Completed | No outcome recorded |
| Phase 1 | NCT04205539 | Dec 2021 → Dec 2022 | Alzheimer disease | Neurological Associates of West Los Angeles | Withdrawn | No outcome recorded |
| Phase 1 | NCT04827056 | Nov 2021 → May 2023 | alcohol-related disorders, post-traumatic stress disorder | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | Completed | No outcome recorded |
| Phase 1 | NCT05124067 | Oct 2021 → Jan 2022 | delirium | Tanta University | Completed | No outcome recorded |
| Phase 1 | NCT04941040 | Jul → Oct 2021 | supratentorial cancer | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04658732 | Dec 2020 → Jun 2021 | — | Ehab Tarek Fahmy | Unknown | No outcome recorded |
| Phase 1 | NCT04062123 | Jul 2020 → Apr 2024 | — | Keith M Vogt | Completed | No outcome recorded |
| Phase 1 | NCT04531371 | Jun → Sep 2020 | — | South Valley University | Unknown | No outcome recorded |
| Phase 1 | NCT04200235 | Jan → Aug 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03668951 | Aug 2018 → May 2022 | heart disorder | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT03417999 | Jun 2018 → Oct 2021 | congenital heart disease | Children's Hospital of Philadelphia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03293277 | Jul 2017 → Jul 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03126422 | May → Sep 2017 | — | Yangzhou University | Unknown | No outcome recorded |
| Phase 1 | NCT02652507 | Jun 2016 → May 2018 | — | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT02836431 | Jan 2016 → Dec 2017 | heart disorder | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT02515890 | Nov 2015 → Dec 2018 | amnestic disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT02250820 | Nov 2014 → Dec 2017 | heart disorder | Children's Hospital Medical Center, Cincinnati | Completed | Missed primary |
| Phase 1 | NCT01915277 | Apr 2014 → Oct 2017 | tetralogy of fallot, transposition of the great arteries, ventricular septal defect | Carelon Research | Completed | No outcome recorded |
| Phase 1 | NCT01342328 | May → Nov 2012 | sleep disorder | University of California, San Francisco | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01447875 | May 2011 → Dec 2013 | infectious disease with sepsis | Southeast University, China | Completed | No outcome recorded |
| Phase 1 | NCT01116700 | Dec 2010 → Feb 2012 | epilepsy | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01084473 | Mar → Jun 2010 | — | University of Turku | Completed | No outcome recorded |
| Phase 1 | NCT01736020 | Sep 2009 → Apr 2017 | — | Southern California Institute for Research and Education | Unknown | No outcome recorded |
| Phase 1 | NCT00837187 | Mar → May 2009 | — | University of Turku | Completed | No outcome recorded |
| Phase 1 | NCT00826553 | Jan 2009 → Dec 2013 | delirium, respiratory failure | Vanderbilt University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00747721 | Sep 2008 → Jan 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00576381 | Apr 2006 → Dec 2010 | cardiac ventricle disorder, hypoplastic left heart syndrome, tetralogy of fallot | Athena Zuppa | Completed | No outcome recorded |
| Phase 1 | NCT00142493 | Sep 2004 → Aug 2008 | amnestic disorder | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00573066 | May 2004 → Oct 2006 | hypoplastic left heart syndrome, tetralogy of fallot, tricuspid atresia | Athena Zuppa | Completed | No outcome recorded |
| Phase 1 | NCT00338546 | — | cocaine intoxication | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1/217 trials | ||||||
| Phase 1/2 | NCT07807020 | May 2026 → May 2027 expected | — | Shifa International Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07672301 | Mar 2026 → Jun 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07622355 | Jan → Jun 2026 | thyroid gland disorder | The Second People's Hospital of Huai'an | Completed | No outcome recorded |
| Phase 1/2 | NCT06970678 | Apr → Jun 2025 overdue | — | Alexandria University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07024043 | Mar → Sep 2025 overdue | — | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07099222 | Oct 2024 → Dec 2026 expected | constipation disorder | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06545890 | Aug → Nov 2024 overdue | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06712186 | Jun → Nov 2024 overdue | anxiety disorder, hypertensive disorder | Liaquat National Hospital & Medical College | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04824144 | Jan 2024 → Jan 2026 overdue | delirium | Bruyère Health Research Institute. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04926454 | Sep 2020 → Oct 2021 | neuropathy, painful | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04470050 | Jun 2020 → Feb 2021 | substance withdrawal syndrome | BioXcel Therapeutics Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT05369468 | Jan 2020 → Nov 2022 | — | Tanta University | Completed | No outcome recorded |
| Phase 1/2 | NCT02818569 | Oct 2016 → Jun 2018 | insomnia | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02409810 | Apr 2015 → Mar 2020 | anxiety | Ohio State University | Completed | No outcome recorded |
| Phase 1/2 | NCT03613558 | Jul 2014 → Jun 2015 | obstructive sleep apnea syndrome | Montefiore Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01664520 | Jun 2013 → Nov 2016 | brain aneurysm, subarachnoid hemorrhage | Turku University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01606852 | Mar 2013 → Jul 2014 | acute respiratory failure, anxiety | University of Minnesota | Completed | No outcome recorded |
| Phase 263 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT07588802 | Sep 2026 → Apr 2027 expected | — | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07705022 | Jul 2026 → Jan 2028 expected | — | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06943404 | Feb → Sep 2026 overdue | acute stress disorder, post-traumatic stress disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 2 | NCT07392177 | Feb 2026 → Mar 2027 expected | insomnia | Woolcock Institute of Medical Research | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07249827 | Dec 2025 → Jun 2026 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 2 | NCT07519863 | Nov 2025 → Nov 2026 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2 | NCT05057689 | Sep → Oct 2025 | acute stress disorder, anxiety | Nationwide Children's Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT07168720 | Aug 2025 → Mar 2026 overdue | — | Guangzhou Novaken Pharm Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06985290 | Jul 2025 → Sep 2027 expected | brain hypoxia - ischemia | Ipsita Goswami | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06979791 | Jun 2025 → May 2026 | — | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT07202624 | Feb → Jun 2025 | pharyngitis | Prince Sultan Military Medical City | Completed | No outcome recorded |
| Phase 2 | NCT06736483 | Feb 2025 → Jul 2027 expected | — | University Hospital, Montpellier | Recruiting | No outcome recorded |
| Phase 2 | NCT06978192 | Dec 2024 → Feb 2026 overdue | herpes zoster | Fenghui Deng | Recruiting | No outcome recorded |
| Phase 2 | NCT06067893 | Jul 2024 → Jul 2027 expected | adolescent idiopathic scoliosis | Nichole Doyle | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06148311 | Jul 2024 → Jan 2027 expected | Riley-Day syndrome | NYU Langone Health | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06128356 | Jun 2024 → Sep 2028 expected | Riley-Day syndrome | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06302998 | Jun 2024 → Dec 2025 | infectious disease with sepsis | Mansoura University | Unknown | No outcome recorded |
| Phase 2 | NCT05616364 | Mar 2023 → Mar 2024 | benign shuddering attacks | Sana Bahadur | Unknown | No outcome recorded |
| Phase 2 | NCT05303987 | Oct 2022 → Jan 2027 expected | obstructive sleep apnea syndrome | Erin Kirkham | Recruiting | No outcome recorded |
| Phase 2 | NCT05487196 | Sep 2022 → Jul 2023 | pregnancy disorder | Grace Lim, MD, MS | Completed | No outcome recorded |
| Phase 2 | NCT07081581 | Aug 2022 → Feb 2023 | breast cancer | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| Phase 2 | NCT04772222 | Jun 2022 → Jan 2025 | brain hypoxia - ischemia | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT05216055 | Apr → Dec 2022 | large intestine disorder | University of Colorado, Denver | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05283083 | Mar 2022 → Feb 2023 | infectious disease with sepsis | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT04391361 | Nov 2020 → Sep 2023 | amyotrophic lateral sclerosis | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06289335 | Aug 2020 → Sep 2021 | — | Hospital Central "Dr. Ignacio Morones Prieto" | Completed | No outcome recorded |
| Phase 2 | NCT04426552 | Jun → Sep 2020 | craniofacial and skeletal defects | Alexandria University | Unknown | No outcome recorded |
| Phase 2 | NCT04382170 | Jun 2020 → Jun 2021 | delirium | Jeff C. Huffman, MD | Withdrawn | No outcome recorded |
| Phase 2 | NCT03957304 | Feb 2020 → Mar 2022 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT04027829 | Aug → Nov 2019 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03989609 | Jun 2019 → Feb 2020 | infectious disease with sepsis | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03807297 | Jan → Nov 2019 | — | Rajiv Gandhi Cancer Institute & Research Center, India | Completed | No outcome recorded |
| Phase 2 | NCT03545516 | Sep → Nov 2018 | substance-related disorder | Richmond University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03645603 | Aug 2018 → Jan 2020 | substance withdrawal syndrome | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Terminated | Missed primary |
| Phase 2 | NCT03979469 | Aug 2018 → Aug 2019 | — | Athens General Children's Hospital "Pan. & Aglaia Kyriakou" | Completed | No outcome recorded |
| Phase 2 | NCT03293927 | Apr 2018 → Jul 2019 | delirium | Duke University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03799783 | Mar 2018 → Feb 2019 | disruptive behavior disorder | Azienda Ospedaliera di Padova | Completed | No outcome recorded |
| Phase 2 | NCT03434366 | Jan 2018 → Dec 2023 | autism spectrum disorder | Guangzhou Women and Children's Medical Center | Suspended | No outcome recorded |
| Phase 2 | NCT03827408 | Nov 2017 → Aug 2019 | — | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 2 | NCT03348423 | Nov 2017 → Jan 2018 | — | Baudax Bio | Completed | No outcome recorded |
| Phase 2 | NCT03222323 | Jul 2017 → Jan 2018 | — | Zealand University Hospital | Unknown | Mixed |
| Phase 2 | NCT03425734 | May 2017 → May 2018 | congenital heart disease | Mai Madkour | Unknown | No outcome recorded |
| Phase 2 | NCT03102359 | Apr 2017 → Dec 2019 | — | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT02675049 | Jan → Feb 2016 | — | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02488473 | Aug → Sep 2015 | — | Zealand University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01969903 | Nov 2014 | — | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT02284243 | Oct 2014 → Jun 2015 | — | Baudax Bio | Completed | Met primary |
| Phase 2 | NCT02169336 | Jun → Sep 2014 | neuropathy, painful | Baudax Bio | Terminated | No outcome recorded |
| Phase 2 | NCT02492269 | May 2014 → Dec 2024 | congenital heart disease | Aymen N Naguib | Completed | No outcome recorded |
| Phase 2 | NCT02252523 | Apr 2014 → Apr 2015 | brain injury | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT02375243 | Feb 2014 → Dec 2015 | — | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02866409 | Nov 2013 → Dec 2014 | headache disorder | NAVNEH SAMAGH | Completed | No outcome recorded |
| Phase 2 | NCT02225054 | May 2013 → Mar 2015 | arthropathy, neurological pain disorder | Women's College Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01687751 | Nov 2012 → Nov 2014 | delirium | Fraser Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT01701778 | Oct 2012 → Jan 2014 | cryptorchidism | Yao Yusheng | Completed | Met primary |
| Phase 2 | NCT01845441 | Apr 2012 → Dec 2021 | brain ischemia, intracranial vasospasm, stroke disorder | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01378988 | Jun → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01007773 | Jan 2010 → Jan 2011 | traumatic brain injury | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 2 | NCT00464451 | Aug 2009 → Dec 2010 | — | Wesley Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00652028 | Nov 2008 → Apr 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00697788 | Jul 2007 → Dec 2008 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00351299 | Jan 2006 → Oct 2012 | delirium | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00505804 | Jan 2005 → Nov 2008 | delirium | Austin Health | Completed | No outcome recorded |
| Phase 2/351 trials · 2 met primary · 2 missed | ||||||
| Phase 2/3 | NCT07810556 | Oct 2026 → Oct 2027 expected | delirium | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07537894 | Jul 2026 → Jul 2027 | post-traumatic stress disorder, pregnancy disorder with abortive outcome | Stanford University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT07493785 | Jun 2026 → Aug 2032 expected | neonatal respiratory failure, neurodevelopmental disorder | Centre Hospitalier Intercommunal Creteil | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07538284 | May → Dec 2026 expected | delirium, sleep disorder | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07555821 | Apr → Oct 2026 expected | — | South Egypt Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06935292 | Apr 2025 → Apr 2026 overdue | — | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06799442 | Mar → Dec 2025 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07290595 | Jan 2025 → Feb 2026 overdue | hypotensive disorder | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06752616 | Dec 2024 → Dec 2027 expected | — | Lone Baandrup | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06662175 | Nov 2024 → Jul 2025 overdue | — | Lady Reading Hospital, Pakistan | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06899841 | Oct 2024 → Oct 2025 overdue | — | Assiut University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06620393 | Oct 2024 → Jun 2026 overdue | traumatic brain injury | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06740903 | Aug 2024 → Aug 2025 overdue | cholecystitis | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07368075 | Jul 2024 → Oct 2025 | hypotensive disorder | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT07064720 | Jul 2024 → Dec 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT06382831 | Jun → Aug 2024 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06378827 | Apr → Jul 2024 | acute kidney injury | University of Novi Sad | Unknown | Missed primary |
| Phase 2/3 | NCT07590752 | Mar 2024 → Jun 2026 overdue | neuropathy, painful, substance-related disorder | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07241351 | Mar → Nov 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT06394375 | Jul → Oct 2023 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT04106999 | Mar 2023 → Jun 2024 | cancer | University of British Columbia | Unknown | No outcome recorded |
| Phase 2/3 | NCT05579964 | Oct 2022 → Apr 2023 | tetralogy of fallot | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
| Phase 2/3 | NCT04656470 | Mar 2022 → May 2025 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT06531603 | Feb 2022 → Jan 2023 | hypotensive disorder | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT05300802 | Dec 2021 → May 2022 | congenital heart disease | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
| Phase 2/3 | NCT05375188 | Aug 2021 → Jan 2022 | acute kidney injury | National Institute of Cardiovascular Diseases, Pakistan | Completed | No outcome recorded |
| Phase 2/3 | NCT03285087 | Jun 2021 → Aug 2022 | — | Assiut University | Suspended | No outcome recorded |
| Phase 2/3 | NCT06735443 | Mar 2021 → Apr 2022 | hernia, double inguinal | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT04383418 | May 2020 → Jun 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04195256 | Mar 2020 → Dec 2026 expected | — | Naveen Poonai | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04971759 | Dec 2019 → Dec 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT04115449 | Nov 2019 → May 2021 | — | Theodor Bilharz Research Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT04237532 | Aug 2019 → Aug 2020 | — | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 2/3 | NCT04042727 | Aug 2019 → Dec 2021 | atrial fibrillation | Stony Brook University | Terminated | No outcome recorded |
| Phase 2/3 | NCT04968392 | Mar 2019 → Feb 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02856594 | Mar 2017 → Feb 2022 | delirium | Massachusetts General Hospital | Completed | Met primary |
| Phase 2/3 | NCT02819141 | Nov 2016 → Oct 2024 | anxiety, respiratory failure | Mayo Clinic | Completed | Mixed |
| Phase 2/3 | NCT02854904 | Aug → Nov 2016 | osteoarthritis, spine, spondylolisthesis, spondylolysis | Sarah Network of Rehabilitation Hospitals | Unknown | No outcome recorded |
| Phase 2/3 | NCT03936205 | Aug 2016 → Oct 2017 | metastatic malignant neoplasm | Hotel Dieu de France Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02713191 | Mar 2016 → Feb 2017 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | Met primary |
| Phase 2/3 | NCT02495220 | Jul 2015 → Nov 2017 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01733043 | Mar → May 2015 | obstructive sleep apnea syndrome | Duke University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT02237495 | Apr 2014 → Mar 2017 | coronary artery disorder, heart valve disorder | Xijing Hospital | Completed | Missed primary |
| Phase 2/3 | NCT01508455 | Mar → May 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT01314209 | Mar 2011 → Mar 2014 | acute kidney injury | Helsinki University Central Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01188551 | Jan 2011 → Apr 2012 | chronic otitis media | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01159262 | Jul 2010 → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT01072643 | Mar 2010 → Mar 2013 | pulmonary hypertension | Aruna Nathan | Terminated | No outcome recorded |
| Phase 2/3 | NCT00815893 | Aug 2008 → Aug 2009 | — | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00608231 | Jan 2008 → Jan 2012 | Parkinson disease, dystonic disorder, essential tremor | Vanderbilt University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00714857 | Oct 2007 → Dec 2010 | — | University of Turku | Completed | No outcome recorded |
| Phase 3101 trials · 9 met primary · 5 missed | ||||||
| Phase 3 | NCT07542990 | Nov 2026 → Apr 2029 expected | delirium | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07847047 | Oct 2026 → Oct 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07569536 | Sep 2026 → Oct 2028 expected | infectious disease with sepsis | Hospices Civils de Lyon | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07434310 | Jul 2026 → Jul 2027 expected | inflammatory bowel disease | Dr. Naveed Siddiqui | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07627906 | Jul → Dec 2026 expected | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07327879 | Jan → Nov 2026 expected | benign shuddering attacks | Al-Azhar University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06878703 | Oct 2025 → Dec 2027 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT07184801 | Oct 2025 → Oct 2026 expected | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 3 | NCT06259565 | Jul 2025 → Dec 2029 expected | — | St. Joseph's Healthcare Hamilton | Recruiting | No outcome recorded |
| Phase 3 | NCT06875427 | Jul 2025 → Jan 2027 expected | — | Isabella Jaramillo | Recruiting | No outcome recorded |
| Phase 3 | NCT07426081 | Jun → Nov 2025 | — | Patel Hospital, Pakistan | Completed | No outcome recorded |
| Phase 3 | NCT06619912 | Mar 2025 → Aug 2026 | delirium, sleep disorder | Xijing Hospital | Completed | No outcome recorded |
| Phase 3 | NCT07350928 | Mar 2025 → Mar 2026 overdue | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06192615 | Jan 2025 → Oct 2027 expected | delirium | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07557680 | Jan → Jun 2025 | hypertensive disorder | Sindh Institute of Urology and Transplantation | Completed | No outcome recorded |
| Phase 3 | NCT06665438 | Dec 2024 → Apr 2025 overdue | — | Al-Azhar University | Recruiting | No outcome recorded |
| Phase 3 | NCT06991647 | Oct → Dec 2024 | — | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT06370442 | Jun 2024 → May 2025 | mental disorder | State University of New York - Upstate Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06281561 | May → Nov 2024 | sleep disorder | The First Affiliated Hospital of Xiamen University | Unknown | Met primary |
| Phase 3 | NCT05383495 | Dec 2023 → Dec 2025 overdue | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 3 | NCT06139926 | Dec 2023 → Jun 2024 | colorectal cancer | First Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT05681572 | Apr 2023 → Oct 2027 expected | — | University Hospital, Montpellier | Recruiting | No outcome recorded |
| Phase 3 | NCT05634148 | Dec 2022 → Apr 2023 | delirium | Security Forces Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05439005 | Dec 2022 → Jun 2027 expected | breast cancer | Institut Curie | Recruiting | No outcome recorded |
| Phase 3 | NCT05641064 | Nov 2022 → Sep 2024 | aortic valve stenosis | University Hospital Dubrava | Completed | No outcome recorded |
| Phase 3 | NCT05615727 | Sep 2022 → Sep 2023 | insomnia | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT05481281 | Aug 2022 → Jan 2023 | — | Hamdard University | Unknown | No outcome recorded |
| Phase 3 | NCT05493228 | May 2022 → Apr 2023 | spinal cord cancer | Children's Cancer Hospital Egypt 57357 | Unknown | No outcome recorded |
| Phase 3 | NCT05311722 | Apr → Dec 2022 | — | Sheikh Zayed Medical College | Unknown | No outcome recorded |
| Phase 3 | NCT05485519 | Apr 2022 → May 2024 | substance withdrawal syndrome | King Abdullah International Medical Research Center | Unknown | No outcome recorded |
| Phase 3 | NCT05489900 | Apr → Jul 2022 | — | Federal University of Rio de Janeiro | Unknown | No outcome recorded |
| Phase 3 | NCT05099055 | Mar 2022 → Jan 2023 | — | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05192629 | Mar 2022 → Jun 2023 | — | Brugmann University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04878510 | Mar 2022 → Apr 2024 | respiratory failure | St. Joseph's Healthcare Hamilton | Completed | No outcome recorded |
| Phase 3 | NCT05849597 | Mar 2022 → Feb 2025 overdue | delirium | University of Novi Sad | Recruiting | No outcome recorded |
| Phase 3 | NCT05233683 | Mar 2022 → Mar 2023 | childhood acute lymphoblastic leukemia | King Saud University | Unknown | No outcome recorded |
| Phase 3 | NCT05072704 | Feb 2022 → Feb 2023 | — | CMC Ambroise Paré | Completed | Missed primary |
| Phase 3 | NCT05191745 | Jan 2022 → Apr 2023 | — | Jewish General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05111431 | Nov 2021 → May 2022 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT04955158 | Aug 2021 → Feb 2023 | pharyngitis | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04940689 | Jul 2021 → Aug 2024 | — | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 3 | NCT04941508 | Jun → Nov 2021 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04928391 | Jun 2021 → Mar 2026 | cleft palate | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04928300 | Jun 2021 → Jul 2027 expected | — | Assiut University | Recruiting | No outcome recorded |
| Phase 3 | NCT04621110 | Jun → Sep 2021 | childhood malignant neoplasm | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04910477 | Jun → Sep 2021 | headache disorder | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04144933 | May 2021 → Jul 2024 | paralytic ileus | University of Saskatchewan | Unknown | No outcome recorded |
| Phase 3 | NCT04576975 | Apr → Dec 2021 | morbid obesity | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT04709315 | Oct 2020 → Jan 2021 | — | South Valley University | Unknown | No outcome recorded |
| Phase 3 | NCT04276883 | Feb → May 2020 | bipolar disorder | BioXcel Therapeutics Inc | Completed | Met primary |
| Phase 3 | NCT04197570 | Feb → Mar 2020 | substance-related disorder | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT04268303 | Jan → May 2020 | schizoaffective disorder, schizophrenia, schizophreniform disorder | BioXcel Therapeutics Inc | Completed | Met primary |
| Phase 3 | NCT04081545 | Dec 2019 → Mar 2023 | substance-related disorder | Christine Oryhan | Completed | No outcome recorded |
| Phase 3 | NCT03953677 | Oct 2019 → Jan 2023 | infectious disease with sepsis | Centre Hospitalier Universitaire Dijon | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT06185127 | Sep 2019 → May 2020 | lung disorder | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT03834129 | May 2019 → Jan 2020 | — | CMC Ambroise Paré | Completed | Missed primary |
| Phase 3 | NCT03530371 | May 2019 → Nov 2021 | — | Fondation Lenval | Completed | No outcome recorded |
| Phase 3 | NCT03653832 | Dec 2018 → Dec 2023 | — | University of Edinburgh | Completed | Missed primary |
| Phase 3 | NCT03151863 | Nov 2018 → Jun 2021 | — | Walid HABRE | Terminated | No outcome recorded |
| Phase 3 | NCT03640390 | Aug 2018 → Aug 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT03524950 | Jun 2018 → Dec 2019 | leiomyoma | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04276545 | Jan 2018 → Mar 2020 | hemorrhagic disease | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT03317067 | Dec 2017 → May 2021 | delirium | University Hospital, Clermont-Ferrand | Completed | Met primary |
| Phase 3 | NCT03316339 | Nov 2017 → Jan 2019 | substance-related disorder | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT03089905 | Aug 2017 → Oct 2026 expected | poisoning | Murdoch Childrens Research Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03115047 | May 2017 → Aug 2020 | — | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 3 | NCT03117023 | Apr → May 2017 | gastric cancer | Nanjing PLA General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03151668 | Jan 2017 → Mar 2018 | infectious disease with sepsis | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02752477 | Aug 2016 → Sep 2020 | chronic pain syndrome | Ben Lim | Unknown | No outcome recorded |
| Phase 3 | NCT02757625 | Jul 2016 → May 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02787018 | Jun 2016 → Sep 2018 | — | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02880540 | Mar 2016 → Feb 2018 | obesity disorder | Janelle Vaughns | Completed | No outcome recorded |
| Phase 3 | NCT02638545 | Sep 2015 → Jan 2017 | infectious disease with sepsis | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 3 | NCT02559102 | Jul 2015 → Jul 2020 | hernia, double inguinal, neurodevelopmental disorder | KK Women's and Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02512809 | Jul 2015 → Oct 2017 | hydrocephalus, poisoning | Nationwide Children's Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02466022 | Jun → Nov 2015 | — | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT02250703 | Sep 2014 → Sep 2016 | — | University of Mississippi Medical Center | Completed | Met primary |
| Phase 3 | NCT02540070 | Aug 2014 → Dec 2017 | osteoarthritis, knee | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 3 | NCT02282787 | Jan 2014 → Jan 2015 | — | King Saud University | Unknown | No outcome recorded |
| Phase 3 | NCT01973452 | Oct 2013 → Dec 2022 | — | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01283412 | Jun 2013 → Jun 2014 | delirium | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT01557270 | Mar → Nov 2012 | — | Prof. Peter Gerner, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT01565590 | Feb 2012 → Jul 2015 | acquired aneurysmal subarachnoid hemorrhage | University of Cincinnati | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01266252 | Jul 2011 → Apr 2017 | neonatal respiratory failure | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 3 | NCT01438957 | Jun → Nov 2011 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01140529 | May 2010 → May 2012 | delirium | Thorax-Kärlkliniken | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01091818 | Mar 2010 → Oct 2011 | — | Ullevaal University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01076816 | Dec 2009 → Feb 2011 | respiratory failure | University Hospital, Ghent | Terminated | No outcome recorded |
| Phase 3 | NCT01083797 | Dec 2009 → Mar 2013 | brain disorder | Federal University of Minas Gerais | Completed | No outcome recorded |
| Phase 3 | NCT00857727 | Aug 2009 → Nov 2011 | — | St. Luke's-Roosevelt Hospital Center | Completed | No outcome recorded |
| Phase 3 | NCT00921284 | Jun 2009 → Jul 2011 | — | Hopital Foch | Completed | No outcome recorded |
| Phase 3 | NCT00926705 | Jun 2008 → Jan 2009 | — | University of Jordan | Completed | No outcome recorded |
| Phase 3 | NCT00526760 | Oct 2007 → Jun 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00479661 | May 2007 → Mar 2010 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00464763 | Apr → Sep 2007 | delirium | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT00460473 | Apr → Nov 2007 | delirium | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00468052 | Mar 2007 → May 2008 | obstructive sleep apnea syndrome | University of Medicine and Dentistry of New Jersey | Completed | Met primary |
| Phase 3 | NCT00398827 | Dec 2006 → May 2007 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00480740 | Dec 2006 → Oct 2011 | atrial septal defect, patent ductus arteriosus | Children's National Research Institute | Completed | Missed primary |
| Phase 3 | NCT00383890 | Aug 2006 → Jan 2007 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT00226785 | Oct 2005 → Jul 2006 | — | Orion Corporation, Orion Pharma | Terminated | Missed primary |
| Phase 4404 trials · 16 met primary · 13 missed | ||||||
| Phase 4 | NCT06946277 | Nov 2026 → May 2027 expected | osteoarthritis, hip | China International Neuroscience Institution | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07855536 | Nov 2026 → Nov 2027 expected | benign shuddering attacks | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07807579 | Oct 2026 → Nov 2027 expected | traumatic brain injury | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07852039 | Oct 2026 → Oct 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07855068 | Oct 2026 → Oct 2027 expected | nephrolithiasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07837492 | Oct 2026 → Oct 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07820540 | Sep 2026 → Jun 2027 expected | — | Benha University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07597109 | Sep 2026 overdue | arterial disorder | Insel Gruppe AG, University Hospital Bern | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07836205 | Sep 2026 → Sep 2028 expected | — | Beijing Chao Yang Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644663 | Jun → Aug 2026 overdue | — | Fudan University | Not yet recruiting | No outcome recorded |
| Show all 404 trials opens the full record — a long page | ||||||
| Phase not applicable367 trials · 13 met primary · 10 missed | ||||||
| — | NCT07695220 | Dec 2026 → Oct 2028 expected | intracerebral hemorrhage | The Third Affiliated Hospital of Southern Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07860203 | Oct → Dec 2026 expected | adenomyosis, cervical cancer, endometrial cancer, endometriosis +2 | Catherin Zhang | Recruiting | No outcome recorded |
| — | NCT07847580 | Sep 2026 → Jun 2029 expected | coronary artery disorder | Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT05500261 | Sep 2026 → Jul 2028 expected | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT07806162 | Sep → Oct 2026 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07657715 | Aug 2026 → Dec 2027 expected | infectious disease with sepsis | First Affiliated Hospital of Wannan Medical College | Not yet recruiting | No outcome recorded |
| — | NCT07677215 | Jul 2026 → Sep 2027 expected | osteoarthritis, knee | Poznan University of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07678216 | Jul 2026 → Jun 2028 expected | traumatic brain injury | Aswan University | Not yet recruiting | No outcome recorded |
| — | NCT07832214 | Jul → Nov 2026 expected | — | Sohag University | Active not recruiting | No outcome recorded |
| — | NCT07699523 | Jun 2026 → Jun 2027 expected | electroencephalographic peculiarity: fronto-precentral beta wave groups | China-Japan Friendship Hospital | Not yet recruiting | No outcome recorded |
| Show all 367 trials opens the full record — a long page | ||||||
| Comparator or background therapy739 trials | ||||||
| Phase 0 | NCT07485127 Comparator | Feb → Aug 2026 overdue | — | Sohag University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT07012213 Comparator | Oct → Nov 2025 overdue | — | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06741566 Comparator | Dec 2024 → May 2026 overdue | — | Minia University | Recruiting | No outcome recorded |
| Phase 0 | NCT06607861 Comparator | Jun 2024 → Jun 2026 overdue | — | Minia University | Recruiting | No outcome recorded |
| Phase 0 | NCT05829148 Comparator | May 2023 → Nov 2024 | — | Egymedicalpedia | Unknown | No outcome recorded |
| Show all 739 trials opens the full record — a long page | ||||||
Press releases naming this drug 84 releases
Evidence & citations 50 cited values
Every value below carries the sentence it was read from. 1,860 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dexmedetomidine | “Dexmedetomidine-esketamine combination (1 μg/mL dexmedetomidine and 0.5 mg/mL esketamine) will be administered after anesthesia induction, firstly as a loading dose at a rate...” NCT07576517 ↗1806“Dexmedetomidine is a potent selective α 2 adrenoceptor agonist that was reported in many previous studies as an adjunct to regional and general anesthesia, with significant...” NCT05385523 ↗ “The aim of this study will be to investigate the population pharmacokinetics and pharmacodynamics of rectal dexmedetomidine Niosomes for Postoperative Analgesia in Pediatric...” NCT05340725 ↗ “Dexmedetomidine, a novel α2-agonist with an eight-fold affinity for α2-adrenergic receptors (sedate and analgesic effects) as clonidine, while exerts much less α1-effects., has...” NCT05727098 ↗ “patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of...” NCT07513935 ↗ “General anesthesia without intraoperative opioids using dexmedetomidine, ketamine, lidocaine, sevoflurane, non-opioid co-analgesics, procedure-specific regional analgesia, and...” NCT07665463 ↗ “Patient will be given a peripheral nerve block from their treating anesthesiologist before the operation (in the OR) with an conventional ultrasound guided femoral and sciatic...” NCT04697537 ↗ “The investigators will not mandate the sedative type, but rather encourage the use of sedatives that are already routinely used in participating ICUs (typically a...” NCT05849779 ↗ “Dexmedetomidine,an α2 adrenergic agonist,has hypnotic,analgesic, anxiolytic,antisympathetic effects,which could facilitate the sedation of patients while maintaining their...” NCT02613806 ↗ “Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that reduces the release of norepinephrine by inhibiting activity in the locus coeruleus, a key brain...” NCT07167316 ↗ “Intravenous Induction of Anesthesia Using a Mixture of Ketamine and dexmedetomidine in a ratio of 1 mg ketamine to 0.5 ug dexmedetomidine given in a dose of 1mg/kg ketamine and...” NCT07002073 ↗ |
| Known as | (+)-4-(S)-\[1-(2,3-dimethylphenyl ) ethyl\]-1H-imidazole hydrochloride | “Background Information: Dexmedetomidine is an α-adrenoceptor agonist, and its chemical name is (+)-4-(S)-\[1-(2,3-dimethylphenyl ) ethyl\]-1H-imidazole hydrochloride.” NCT02007798 ↗ |
| Known as | Ai Beining | “Dexmedetomidine was developed by the Orion Pharma (Finland) Corporation and Abott (USA), and introduced to China in 2009 (trade name: Ai Beining).” NCT02007798 ↗ |
| Known as | BXCL501 | “Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)” NCT03708315 ↗4“Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg” NCT06335407 ↗ “Sublingual film containing dexmedetomidine (BXCL501)” NCT05974527 ↗ “Sublingual film containing dexmedetomidine (BXCL501)” NCT04268303 ↗ “Sublingual film containing Dexmedetomidine (BXCL501)” NCT04276883 ↗ |
| Known as | DA-9501 | “The purpose of this study is to examine the efficacy and safety of DA-9501 (Dexmedetomidine) in patients who require sedation during the surgery that requires epidural or...” NCT01438957 ↗ |
| Known as | deksmedetomidine | “One commonly used sedative drug is deksmedetomidine, an α2 receptor agonist.” NCT03601091 ↗ |
| Known as | DEM | “perineural dexamethasone (DEX) versus dexmedetomidine (DEM) when used as adjuvants to ropivacaine in pediatric popliteal sciatic nerve blocks” PMID 41043950 ↗ Oct 2025 |
| Known as | DEX | “After surgery, patient-controlled intravenous analgesia will be established with dexmedetomidine (DEX 1.5 ug/ml), esketamine (ESK 0.5 mg/ml), and sufentanil (1.25 ug/ml),...” NCT07523321 ↗103“Dexmedetomidine (Dex) is a new type of highly selective α2-adrenergic receptor agonist, which has the effects of sedative-hypnotic, anti-inflammatory, stress reduction,...” NCT06207331 ↗ “BACKGROUND: Desaturation is a common complication of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Dexmedetomidine (DEX), a commonly used...” PMID 33122573 ↗ May 2021 “Dexmedetomidine (DEX) is a centrally acting alpha-2-adrenoceptor agonist that has potential in the management of alcohol withdrawal syndrome (AWS) owing to its ability to...” PMID 26525052 ↗ Nov 2015 “The goal is to determine if the propofol (PR) (sedative agent), dexmedetomidine (DEX)(selective α2-adrenergic receptor (α2-AR) agonist) or their combination could improve and...” NCT05450497 ↗ “Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation (IMV) that promotes patient wakefulness, has no effect on...” NCT06259565 ↗ “Following Anesthesia induction, dexmedetomidine (DEX) Low Dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.3 µg/kg/h,...” NCT07145814 ↗ “A randomized double-blind controlled trial was conducted to investigate whether the administration of DEX, immediately after delivery and for patient-controlled intravenous...” PMID 32210537 ↗ Mar 2020 “Dexmedetomidine (DEX), a sedative commonly used in EVT, can stabilize hemodynamics by inhibiting the sympathetic nervous system and alleviate ischemia-reperfusion injury...” PMID 38439027 ↗ Mar 2024 “This study aims to evaluate the effect of intranasal dexmedetomidine (Dex) administered before combined spinal-epidural labor analgesia on the incidence of postpartum...” NCT07501728 ↗ “Research focuses on the role of intravenous (IV) nefopam, dexmedetomidine (DEX), and meperidine in averting shivering episodes in adult individuals receiving SA for surgical...” PMID 41346412 ↗ Dec 2025 |
| Known as | Dex,Dexmedetomidine | “Dex,Dexmedetomidine” NCT02552459 ↗ |
| Known as | DEX-IN | “DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.” NCT02284243 ↗ |
| Known as | Dexamed | “Dexmedetomidine (Dexamed) is a selective α2-adrenoceptor agonist with sedative and neuroprotective properties, known to reduce ICP without respiratory depression .” NCT07199595 ↗ |
| Known as | dexamedetomidine | “The needle entry point will be anesthetized with 20 mL 0.25% Rupivacane plus dexamedetomidine 0.25ug/kg.” NCT07368075 ↗ |
| Known as | Dexdomitor | “Dexmedetomidine Injectable Solution [Dexdomitor]” NCT05123170 ↗ |
| Known as | Dexdor | “Currently, two pharmacological α-2 agonists, clonidine (Catapressan®, Boehringer Ingelheim) and dexmedetomidine (Dexdor®, Orion Corporation), are marketed and commonly used in...” NCT04758936 ↗5“1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously...” NCT02724098 ↗ “Dexmedetomidine group (Dex group) : Two administrations of 1 microg/kg of Dexdor® in 250 ml of sodium chloride during 30 min.” NCT03834129 ↗ “It is composed by Dexmedetomidine (Dexdor), Lidocaine, Magnesium Sulfate and ketamine (Ketolar).” NCT05887258 ↗ “Dexmedetomidine (Dexdor®)” NCT02096068 ↗ “Dexdor” NCT04266665 ↗ |
| Known as | Dexemedethomidine | “Dexemedethomidine is given as major sedative drug” NCT01091818 ↗ |
| Known as | DEXM | “Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia.” NCT03791879 ↗ |
| Known as | Dexmedetmodine | “Dexmedetmodine 50mic (0.5ml) ,4 mg dexamethasone (1ml), 40 mg lidocaine 2% (2ml) added to 4ml total volume with sterile saline .” NCT05271721 ↗ |
| Known as | dexmedetomdine | “Transforaminal injection of chronic radicular lower limb injection by either dexmedetomdine or magnesuim sulfate” NCT05271721 ↗ |
| Known as | Dexmedetomedine | “The randomized control trial of Comparison of Ropivacane 0.25% plus Dexamethasone and Ropivacane 0.25% plus Dexmedetomedine will be conducted at department of anaesthesia of...” NCT07368075 ↗ |
| Known as | Dexmedetomidin | “Drug: Dexmedetomidin” NCT07084753 ↗ |
| Known as | Dexmedetomidine HCl | “Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Outpatient Study” NCT06335407 ↗1“BXCL501 (dexmedetomidine HCl) taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.” NCT06943404 ↗ |
| Known as | Dexmedetomidine HCl Injection | “Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira).” NCT03355053 ↗ |
| Known as | Dexmedetomidine Hydrochloride | “1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously...” NCT02724098 ↗39“Dexmedetomidine hydrochloride ,a relatively new drug in Chinais ,is a highly selective, potent a2-adrenoceptor agonist with significant analgesic, sedative and anxiolytic effects.” NCT01864187 ↗ “Dexmedetomidine hydrochloride as a single agent produces sedation, pain relief, anxiety redution, stable respiratory rates, and predictable cardiovascular responses.” NCT00691886 ↗ “Study drugs (either 200 μg/2 ml dexmedetomidine hydrochloride or 2 ml 0.9% saline) were provided as clear aqueous solution in the same type of 3 ml volume ampules” NCT03117790 ↗ “A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline” NCT02757625 ↗ “Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ "dexmedetomidine hydrochloride" - Pfizer) and ketamine.” NCT05674877 ↗ “Dexmedetomidine hydrochloride (Precedex®, manufactured by Hospira, Inc. Lake Forest, IL, and USA) is supplied in 100 μg/ml ampule.” NCT03064633 ↗ “The nasal spray group (Group D) trial medication specification is dexmedetomidine hydrochloride nasal spray at 25μg per spray.” NCT07579806 ↗ “Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection” NCT03290625 ↗ “dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA)” NCT01084473 ↗ “Group 1 (LD) was administered 50 μg of dexmedetomidine hydrochloride nasal spray and 50 μg of placebo nasal spray” NCT07298525 ↗ |
| Known as | dexmedetomidine hydrochloride for injection | “dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).” NCT03289325 ↗ |
| Known as | Dexmedetomidine injection | “Dexmedetomidine Injection [Precedex]” NCT06386783 ↗2“Dexmedetomidine Injection [Precedex]” NCT04659642 ↗ “Drug: Dexmedetomidine injection” NCT06410365 ↗ |
| Known as | Dexmedetomidini hydrochloridum | “Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous” NCT03844841 ↗ |
| Known as | Dexmedetomidinum | “Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous” NCT03844841 ↗ |
| Known as | Dexmeditomidine | “Dexmeditomidine (DEX) has been studied as adjuvant for nerve block to aumnet the pain reliefe.” NCT05624866 ↗ |
| Known as | dexmedtemodine | “hyalase and dexmedtemodine are well known adjuvants given epidurally to alleviate chronic back pain.” NCT05370963 ↗1“epidural transforaminal injection of dexmedtemodine” NCT05271721 ↗ |
| Known as | Dexmetedomidine | “So, to overcome this flaw some adjuvants were proven to prolong the analgesia duration as Dexmetedomidine (Dex), and magnesium.” NCT04498351 ↗ |
| Known as | Dexmetomidine | “To Compare Post-op Analgesic Effectiveness of Ropivicaine+Dexamethasone and Ropivacane+Dexmetomidine in TAP Block in Stoma Reversal Under GA in Terms of Duration of Analgesia.” NCT07368075 ↗ |
| Known as | DEXTOMID | “Study drugs would be prepared as follow In group BD, 0.5% hyperbaric bupivacaine (ANAWIN heavy, Neon Laborotaries, India) 10mg (2ml) with addition of 5 mcg (0.2ml)...” NCT06367660 ↗ |
| Known as | DMET | “For many years, clonidine, an α2-adrenergic receptor (α2-AR) agonist, has been widely used as an analgesic adjuvant in perioperative conditions and pain therapy....” PMID 21283652 ↗ Dec 20101“Dexmedetomidine (DMET), a selective a2-adrenergic agonist” PMID 30824336 ↗ Jan 2019 |
| Known as | DMT | “BACKGROUND: Dexmedetomidine (DMT), a highly selective α2-adrenoceptor agonist, has been used safely as a sedative in patients under regional anesthesia.” PMID 25971886 ↗ Jan 20152“Dexmedetomidine (DMT) has been shown to prolong spinal anaesthesia.” PMID 22220945 ↗ Jan 2012 “dexmedetomidine (DMT)” NCT04772222 ↗ |
| Known as | DMTS | “The primary objective of this study is to evaluate the analgesic efficacy of Dexmedetomidine Transdermal System (DMTS), compared with placebo, in participants following abdominoplasty.” NCT04242407 ↗1“Dexmedetomidine Transdermal System (DMTS) for Post-Operative Analgesia Following Bunionectomy” NCT02953054 ↗ |
| Known as | DXM | “Dexmedetomidine(DXM), a selective 2-adrenoreceptor agonist, has been used in the epidural space in humans without any reports of neurological deficits.” NCT01342562 ↗5“Dexmedetomidine (DXM) loading dose of 0.6 µg/kg followed by DXM infusion given at a rate of 0.4 ml/kg/h and was provided as 0.15 µg/kg/h for 24-h PO.” NCT06907277 ↗ “Dexmedetomidine (DXM) a highly selective α2 adrenergic agonist with sedative, anxiolytic, analgesic, sympatholytic and antihypertensive effects.” NCT06837844 ↗ “Dexmedetomidine (DXM) is a selective α2-adrenergic agonist with analgesic properties.” NCT06685081 ↗ “Dexmedetomidine (DXM) is a potent and highly selective α2-adrenergic agonist” NCT06470854 ↗ “Dexmedetomidine (DXM) is a recently released and approved alpha 2 agonist” NCT02102139 ↗ |
| Known as | Hydrochloric acid right-metomidine | “Hydrochloric acid right-metomidine is an alpha2-adrenaline receptor agonisant developed by Orion Pharma (Finland) and Abott (Usa) in collaboration.” NCT04652427 ↗ |
| Known as | Igalmi | “Participants receive a single 120 mcg dose of sublingual dexmedetomidine (IGALMI®) administered approximately 15-20 minutes before the scheduled sleep opportunity during the...” NCT07800910 ↗1“Sublingual film containing 180 µg of Igalmi (dexmedetomidine)” NCT06041646 ↗ |
| Known as | IN-DEX | “Recently we have introduced Intra-nasal Dexmedetomidine (IN DEX), with an initial impression of much improved drug acceptance and possibly improved efficacy over TFS.” NCT04270708 ↗1“Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.” NCT02211118 ↗ |
| Known as | Percedex | “The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )” NCT03892512 ↗ |
| Known as | Precedex | “The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of...” NCT06052111 ↗85“35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused...” NCT05703048 ↗ “Patients with COPD scheduled for outpatient FB will be provided with an intravenous infusion of dexmedetomidine (1 mcg/kg/hr) (Precedex®: Hospira, Inc, Lake Forest, IL) over a...” NCT00401206 ↗ “Dexmedetomidine 0.25 µg/kg loading dose will be infused intravenously over 10 minutes through syringe pump before surgery in the control group (Prepared using Precedex vial...” NCT04658732 ↗ “Patients will receive dexmedetomidine (Precedex®; 200 µg/2 ml; at one µg/kg loading dose over 10 minutes followed by a 0.5 µg/kg/hr. maintenance dose for 48 hours...” NCT06490731 ↗ “a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of...” NCT04148599 ↗ “The purpose of this study is to see if the drug, Dexmedetomidine (also known as Precedex), can reduce pain for patients having Thoracic Surgery and therefore reduce the amount...” NCT01973452 ↗ “Dexmedetomidine (Precedex) is a highly selective alpha 2 adrenoreceptor agonist which produce sedation, anxiolysis, analgesia, and decreasing inflammatory response to...” NCT06514040 ↗ “Dexmedetomidine (Precedex) is a highly selective α2-adrenergic agonist with the properties of analgesia, sedative, anxiolytic and neuroprotection without significant...” NCT07398066 ↗ “will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI” NCT04426552 ↗ “Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure.” NCT04621110 ↗ |
| Known as | Precedex (dexmedetomidine hydrochloride; Pfizer Inc, NY, Ny) | “Precedex (dexmedetomidine hydrochloride; Pfizer Inc, NY, Ny)” NCT03355053 ↗ |
| Known as | Precedex, dexmedetomidine HCl | “Precedex, dexmedetomidine HCl” NCT01915277 ↗ |
| Known as | PrecedexR | “Dexmedetomidine Hydrochloride: PrecedexR 200 µg/2ml vial , Pfizer, Egypt.” NCT06958367 ↗ |
| Known as | PrecedexTM | “Group D patients (n = 30) will be administer 0.5 mcg/kg dexmedetomidine (PrecedexTM; Hospira Inc., Lake Forest, IL, USA) intravenously over 10 min.” NCT06712186 ↗2“Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection” NCT03290625 ↗ “The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml).” NCT03451227 ↗ |
| Known as | precidex | “Inj. Dexmedetomidine (precidex) 200/mcg/2ml given to participants in infusion form for 10 mins of surgery and maintenance dose given till the end of surgery” NCT05337085 ↗1“Inj.Dexmedetomidine(precidex ) 200mcg/2ml Given to participants in infusion form for 24 hours” NCT05264077 ↗ |
| Action | Activate | “dexmedetomidine (an alpha2 adrenoceptor agonist)” PMID 20233428 ↗ Mar 2010 |
| Modality | Other / unclassified | “a potent alpha2 adrenoceptor agonist” NCT01569048 ↗ |
| Route | Intravenous | “Intravenous Dexmedetomidine With Propofol/Midazolam” NCT00226785 ↗ |
| Target | ADRA2A | “a highly selective α2A-adrenergic receptor (ADRA2A) agonist” PMID 31168973 ↗ Jul 2019 |